Neutrophil elastase inhibitors
- 16 January 2011
- journal article
- review article
- Published by Taylor & Francis Ltd in Expert Opinion on Therapeutic Patents
- Vol. 21 (3), 339-354
- https://doi.org/10.1517/13543776.2011.551115
Abstract
Introduction: Chronic obstructive pulmonary disease (COPD) constitutes a worldwide health problem. There is currently an urgent and unmet need for the development of small molecule therapeutics capable of blocking and/or reversing the progression of the disorder. Recent studies have greatly illuminated our understanding of the multiple pathogenic processes associated with COPD. Of paramount importance is the key role played by proteases, oxidative stress, apoptosis and inflammation. Insights gained from these studies have made possible the exploration of new therapeutic approaches. Areas covered: An overview of major developments in COPD research with emphasis on low-molecular mass neutrophil elastase inhibitors is described in this review. Expert opinion: Great strides have been made toward our understanding of the biochemical and cellular events associated with COPD. However, our knowledge regarding the inter-relationships among the multiple pathogenic mechanisms and their mediators involved is still limited. The problem is further compounded by the unavailability of suitable validated biomarkers for assessing the efficacy of potential therapeutic interventions. The complexity of COPD suggests that effective therapeutic interventions may require the administration of more than one agent such as a human neutrophil elastase or MMP-12 inhibitor with an anti-inflammatory agent such as a PDE4 inhibitor or a dual function agent capable of disrupting the cycle of proteolysis, apoptosis, inflammation and oxidative stress.Keywords
This publication has 107 references indexed in Scilit:
- Inhibitors of human neutrophil elastase based on a highly functionalized N-amino-4-imidazolidinone scaffoldEuropean Journal of Medicinal Chemistry, 2010
- A human surfactant peptide-elastase inhibitor construct as a treatment for emphysemaProceedings of the National Academy of Sciences of the United States of America, 2010
- The tissue inhibitors of metalloproteinases (TIMPs): An ancient family with structural and functional diversityBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2010
- Neutrophil elastase–mediated degradation of IRS-1 accelerates lung tumor growthNature Medicine, 2010
- Mechanism-based inhibitors of serine proteases with high selectivity through optimization of S′ subsite bindingBioorganic & Medicinal Chemistry, 2009
- Targeting Nrf2 with the triterpenoid CDDO- imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in miceProceedings of the National Academy of Sciences of the United States of America, 2009
- Proteases and cystic fibrosisThe International Journal of Biochemistry & Cell Biology, 2008
- Neutrophil serine proteases fine-tune the inflammatory responseThe International Journal of Biochemistry & Cell Biology, 2008
- Inhibition of serine proteases by a new class of cyclosulfamide-based carbamylating agentsArchives of Biochemistry and Biophysics, 2008
- The selective MMP‐12 inhibitor, AS111793 reduces airway inflammation in mice exposed to cigarette smokeBritish Journal of Pharmacology, 2008